Primary Immunodeficiency Disorders Market Size, Share & Trends Analysis Report By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders), By Treatment, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Premium Spirits Market Growth & Trends
The global premium spirits market size is expected to reach USD 408.77 billion in 2030, growing at a CAGR of 9.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market has experienced robust growth, driven by consumers' increasing demand for differentiated and high-quality beverage products, even amidst economic challenges. High-income consumers have shown resilience against inflation and recessionary pressures, contributing to this trend.
Notably, in 2022, 33% of Americans spent USD 50 or more on a bottle of alcohol, up from 24% in 2021, according to beveragedaily.com. The spirits segment has benefited from premiumization, with sales growing at about 5.1% year-over-year. More than 60% of the spirits revenue came from high-end and super-premium spirits. The growing popularity of celebrity-endorsed products and reputable brands has also fostered strong customer loyalty. In contrast, while the overall domestic beer market saw a 1.2% decline in sales in 2022, the super-premium beer category experienced a 5% increase, according to the 2023 Beer Report published by Beverage Industry.
In addition to the trend of premiumization, the growth of the premium spirits market is also supported by evolving consumer preferences for unique and artisanal products. There is a growing appreciation for craftsmanship and quality, with consumers increasingly seeking out small-batch and craft spirits that offer distinctive flavors and unique production methods. This trend is particularly evident among millennials and Gen Z consumers, who value authenticity and are willing to pay a premium for products that offer a rich narrative or cultural heritage.
Globally, there are approximately 1.8 billion millennials, constituting 23% of the world's population. In the U.S., they account for around 32% of total craft spirits consumption. However, preferences may vary among different age groups, with Gen Z showing less interest in alcohol due to aging and increased health concerns. Younger millennials, who have recently reached the LDA, appear to be the most lucrative consumer segment. They generate a sizeable demand for innovative and premium beverages.
Premium Spirits Market Report Highlights
Premium Spirits Market Growth & Trends
The global premium spirits market size is expected to reach USD 408.77 billion in 2030, growing at a CAGR of 9.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market has experienced robust growth, driven by consumers' increasing demand for differentiated and high-quality beverage products, even amidst economic challenges. High-income consumers have shown resilience against inflation and recessionary pressures, contributing to this trend.
Notably, in 2022, 33% of Americans spent USD 50 or more on a bottle of alcohol, up from 24% in 2021, according to beveragedaily.com. The spirits segment has benefited from premiumization, with sales growing at about 5.1% year-over-year. More than 60% of the spirits revenue came from high-end and super-premium spirits. The growing popularity of celebrity-endorsed products and reputable brands has also fostered strong customer loyalty. In contrast, while the overall domestic beer market saw a 1.2% decline in sales in 2022, the super-premium beer category experienced a 5% increase, according to the 2023 Beer Report published by Beverage Industry.
In addition to the trend of premiumization, the growth of the premium spirits market is also supported by evolving consumer preferences for unique and artisanal products. There is a growing appreciation for craftsmanship and quality, with consumers increasingly seeking out small-batch and craft spirits that offer distinctive flavors and unique production methods. This trend is particularly evident among millennials and Gen Z consumers, who value authenticity and are willing to pay a premium for products that offer a rich narrative or cultural heritage.
Globally, there are approximately 1.8 billion millennials, constituting 23% of the world's population. In the U.S., they account for around 32% of total craft spirits consumption. However, preferences may vary among different age groups, with Gen Z showing less interest in alcohol due to aging and increased health concerns. Younger millennials, who have recently reached the LDA, appear to be the most lucrative consumer segment. They generate a sizeable demand for innovative and premium beverages.
Premium Spirits Market Report Highlights
- Based on product, the premium tequila market is projected to grow at a CAGR of 12.4% from 2024 to 2030, owing to the increasing interest in tequila-based cocktails, with mixologists experimenting with flavors and infusions to create inventive drink offerings.
- The sales of premium spirits through off-trade channels are expected to grow at a CAGR of 10.9% from 2024 to 2030. The convenience of purchasing spirits from retail channels that offer extensive product listings, competitive pricing, and personalized shopping experiences has made the off-trade channel increasingly popular, especially among millennials and younger demographics who value both quality and convenience.
- The Asia Pacific market for premium spirits is expected to grow at 10.9% from 2024 to 2030. The demand for premium spirits in the Asia Pacific region is experiencing significant growth, propelled by strategic marketing from major brands like Pernod Ricard and Diageo.
- The Europe premium spirit market is anticipated to grow at 9.5% from 2024 to 2030. The rapid rise in demand for premium quality spirits because of altering cultural views among the region's young and affluent population is a primary driver of the spirits market's expansion in the region.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Treatment
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. Treatment outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Primary Immunodeficiency Disorders Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET: DISEASE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Primary Immunodeficiency Disorders Market: Disease Movement Analysis
4.3. Primary Immunodeficiency Disorders Market by Disease Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Antibody Deficiency
4.5.1. Antibody Deficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Cellular Immunodeficiency
4.6.1. Cellular Immunodeficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Innate Immune Disorders
4.7.1. Innate Immune Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Primary Immunodeficiency Disorders Market: Treatment Movement Analysis
5.3. Primary Immunodeficiency Disorders Market by Treatment Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Immunoglobulin Replacement Therapy
5.5.1. Immunoglobulin Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Antibiotic Therapy
5.6.1. Antibiotic Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Stem Cell/Bone Marrow Transplantation
5.7.1. Stem Cell/Bone Marrow Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Gene Therapy
5.8.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Dashboard
6.2. Regional Primary Immunodeficiency Disorders Market movement analysis
6.3. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis by Disease, Biomaterial & End-use
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. North America
6.5.1. North America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. U.S.
6.5.2.1. U.S. Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Canada
6.5.3.1. Canada Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Mexico Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Europe
6.5.6. Europe Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. UK
6.5.7.1. UK Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Germany
6.5.8.1. Germany Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. France
6.5.9.1. France Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.10. Italy
6.5.10.1. Italy Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.11. Spain
6.5.11.1. Spain Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.12. Denmark
6.5.12.1. Denmark Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.13. Norway
6.5.13.1. Norway Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.14. Sweden
6.5.14.1. Sweden Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Japan Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. China Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. India Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. South Korea Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Australia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Thailand Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Brazil Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Argentina Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Middle East & Africa
6.8.1. Middle East & Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. South Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. UAE Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Kuwait Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Baxter International, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Disease benchmarking
7.2.1.4. Strategic initiatives
7.2.2. CSL Behring LLC
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Takeda Pharmaceutical Company Limited
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Octapharma
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Biotest AG
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Grifols, S.A.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Kedrion Biopharma Inc
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Bio Products Laboratory Ltd
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. LFB S.A
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. ADMA Biologics, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Abbott Laboratories
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Astellas Pharma Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Treatment
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. Treatment outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Primary Immunodeficiency Disorders Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET: DISEASE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Primary Immunodeficiency Disorders Market: Disease Movement Analysis
4.3. Primary Immunodeficiency Disorders Market by Disease Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Antibody Deficiency
4.5.1. Antibody Deficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Cellular Immunodeficiency
4.6.1. Cellular Immunodeficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Innate Immune Disorders
4.7.1. Innate Immune Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Primary Immunodeficiency Disorders Market: Treatment Movement Analysis
5.3. Primary Immunodeficiency Disorders Market by Treatment Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Immunoglobulin Replacement Therapy
5.5.1. Immunoglobulin Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Antibiotic Therapy
5.6.1. Antibiotic Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Stem Cell/Bone Marrow Transplantation
5.7.1. Stem Cell/Bone Marrow Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Gene Therapy
5.8.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PRIMARY IMMUNODEFICIENCY DISORDERS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Dashboard
6.2. Regional Primary Immunodeficiency Disorders Market movement analysis
6.3. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis by Disease, Biomaterial & End-use
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. North America
6.5.1. North America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. U.S.
6.5.2.1. U.S. Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Canada
6.5.3.1. Canada Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Mexico Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Europe
6.5.6. Europe Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. UK
6.5.7.1. UK Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Germany
6.5.8.1. Germany Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. France
6.5.9.1. France Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.10. Italy
6.5.10.1. Italy Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.11. Spain
6.5.11.1. Spain Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.12. Denmark
6.5.12.1. Denmark Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.13. Norway
6.5.13.1. Norway Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.14. Sweden
6.5.14.1. Sweden Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Japan Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. China Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. India Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. South Korea Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Australia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Thailand Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Brazil Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Argentina Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Middle East & Africa
6.8.1. Middle East & Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. South Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. UAE Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Kuwait Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Baxter International, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Disease benchmarking
7.2.1.4. Strategic initiatives
7.2.2. CSL Behring LLC
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Takeda Pharmaceutical Company Limited
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Octapharma
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Biotest AG
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Grifols, S.A.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Kedrion Biopharma Inc
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Bio Products Laboratory Ltd
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. LFB S.A
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. ADMA Biologics, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Abbott Laboratories
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Astellas Pharma Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
